Late-stage preclinical research targeting orostate cancer gets $4 million from CIRM
A program hoping to supercharge a patient’s own immune system cells to attack and kill a treatment resistant form of prostate cancer was today awarded $3.99 million by the governing Board of the California Institute for Regenerative Medicine. July 19, 2018